Tag: malignant prostate neoplasm

When to Stop Cancer Screening: Clinicians’ Calculus Varies

Clinicians more often use a strict age cutoff for stopping colon cancer screening than they do for stopping breast and prostate cancer screening, new data...

Rebuilding Trust in Healthcare Key to Recharging Vaccine Uptake

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Left – Dr Richard Baron; Right – Dr Dhruv Khullar Before...

Loneliness in Middle-Aged Men Linked to Increased Cancer Risk

Loneliness among middle-aged men ups their risk of cancer, and being single at the time of diagnosis confers a worse prognosis, suggest results from a...

Cancer Screening Stopped by Pandemic: Repercussions to Come?

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Last year, cancer screening programs around the world ground to a...

CCR Score Can Guide Treatment After Radiation in Prostate Cancer

The combined clinical cell-cycle risk (CCR) score — derived from both clinical and genetic factors — can identify patients with intermediate- and high-risk localized prostate...

Liquid vs Tissue Biopsy in Prostate Cancer: Why Not Both?

The genomic landscape of circulating tumor DNA (ctDNA) was comparable to the landscape of tissue biopsies in a large study of patients with metastatic castration-resistant...

MRI-Guided Prostate Biopsy Prevails in PRECISE Trial

Here’s welcome news for men of a certain age: new results support a less invasive approach to investigations for suspicion of prostate cancer. An approach...

Liquid Biopsies Helpful in Prostate Cancer, but Most Not Ready for Routine Use

NEW YORK (Reuters Health) – Liquid biopsies have the potential to guide therapeutic decision making in prostate cancer, but issues such as assay standardization, cost...

Postprostatectomy Urinary Outcomes Vary Widely by Patient and Surgeon

(Reuters Health) – Patient-reported urinary outcomes three months after radical prostatectomy vary by patient and by surgeon, and a new study suggests that outcomes may...

Doctors Underreport Side Effects of Breast Irradiation

There is a substantial mismatch between patient and physician reports of toxicity during radiotherapy for breast cancer, according to an analysis of nearly 10,000 U.S....

Judge Delays Rule That Cuts Pay for Drugs in Docs’ Offices

The Trump administration has failed to persuade a judge of the need to rush the implementation of major changes in payments for drugs administered in...

FDA OKs First Oral Hormone Tx for Advanced Prostate Cancer

The US Food and Drug Administration (FDA) today approved an oral form of androgen deprivation therapy (ADT) known as relugolix (Orgovyx) for the treatment of...

FDA Approves First Agent for PSMA-PET Imaging in Prostate Cancer

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68...

Hold Off Radiotherapy After Prostate Cancer Surgery

Most men who undergo radical prostatectomy can skip adjuvant radiotherapy and can be followed with observation alone. They can undergo early salvage radiotherapy if the...

Global Stomach Cancer Deaths Decline as CRC Deaths Stagnate, Rise

A global analysis of premature deaths from noncommunicable diseases (NCDs) has shown mixed results for gastrointestinal (GI) cancers. The data suggest fewer people are dying...

New Drug for Prostate Cancer: Ipatasertib, an AKT Inhibitor

The investigational kinase inhibitor ipatasertib (Roche), which targets a key cancer metabolic pathway, has shown promise when used in combination with abiraterone (Zytiga) in the...

Genetic Differences by Ancestry and Prostate Cancer Therapies

There are genetic differences when comparing prostate tumors from African American men and European-American men, but none of these differences are of clinical significance for...

Physicians, Patients Need to Know Limits of DNA Privacy Law

Because of the role genetic testing now plays in the management of cancer, and in the identification of risk for the disease, physicians should make...

Does Obesity Reduce Drug Efficacy in Breast Cancer?

Obesity has been shown to have an impact on the risk of developing breast cancer and on prognosis. A new study suggests that it may...

Hydrogel Injection May Curb Unwanted Radiation From Prostate Radiotherapy

NEW YORK (Reuters Health) – In men receiving prostate radiotherapy, use of a perirectal hydrogel spacer (SpaceOAR, Boston Scientific) may help reduce rectal irradiation and...

‘Every Patient Would Applaud’ Bladder Cancer Surveillance Study

A new, less intensive approach to follow-up of patients with high-risk, non-muscle invasive bladder cancer (NMIBC) after surgery appears feasible. Usually, such patients follow an...

Sexual Distress, Depression After Prostate Cancer Treatment

Nearly one-third of men who have undergone treatment for prostate cancer report that a subsequent lack of sexual function has had the greatest impact on...

FDA Approves Olaparib for Certain Metastatic Prostate Cancers

The US Food and Drug Administration approved olaparib (Lynparza, AstraZeneca) for deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant...

New Drug for GIST, PARPi for Prostate Cancer

Here are the most important stories that Medscape Oncology‘s editors picked for you to read today. FDA Approves Ripretinib for Advanced GISTs The US Food...

First PARP Inhibitor Approved for Metastatic Prostate Cancer

A completely new approach to the treatment of prostate cancer is now available to clinicians through the approval of the first PARP inhibitor for use...